Bram Goorden, CEO of IXICO (LSE:IXI), recently provided an update on the company’s financial performance and strategic vision following the release of its financial results for the year ending September 30, 2025. The interview highlighted IXICO’s continued focus on AI-driven neuroimaging and its commitment to scalable, technology-led solutions for neurological diseases.
Setting the Stage for Sustainable Double-Digit Growth
IXICO, which specializes in AI-driven imaging analysis as a service for pharma and biotech companies developing novel drugs, reported a strong financial turnaround. Goorden noted a 13% growth for the past year and is predicting at least 15% for the upcoming year. He emphasized that the primary business objective is to expand the market and achieve “double digit growth numbers and that we make them sustainable.”
Leveraging Technology for Margin Expansion
A key component of IXICO’s forward-looking strategy is scaling its AI-driven analytics to expand margins. Goorden described this as a “very exciting” second phase, which will involve “leveraging our technology and partnering our technology also with some of these other service providers in the ecosystem.”
Over the next 12 to 24 months, the company plans to not only grow its core CRO (Clinical Research Organization) services but also collaborate with external partners to maximize the use of its proprietary technology, thereby achieving greater profitability.
Dominance in Neurodegenerative Disease
When addressing the competitive landscape in neuroimaging, Goorden clearly defined IXICO’s strategic differentiator: a deep and long-standing focus on neurodegenerative diseases—specifically Alzheimer’s, Parkinson’s, and rare CNS (Central Nervous System) conditions.
After 20 years in the field, Goorden stated that IXICO is an “absolute leader” in this niche. By focusing on neurology, the company is deliberately “staying away… from that red ocean which oncology or cardiology could represent.” This specialized approach is reinforced by a continuous commitment to investing in novel algorithms on their platform, which serves as a core competitive advantage in supporting research for CNS diseases.
Strategic Market and Disease Prioritization
Geographically, IXICO remains a global business, serving the development programs of major pharmaceutical and biotech firms worldwide. While “most of our revenues are coming from the other side of the pond… so in the US,” the company anticipates further expansion, particularly in the biotech arena along the Northeast coast of the US, alongside continued strength in Europe.
In terms of therapeutic areas, the company is committing to going “much deeper” into the dementia space, especially Alzheimer’s, citing a clear unmet need and a place where pharma is “really doubling down their investments.” Furthermore, IXICO plans to maintain its traditionally strong position in rare CNS diseases like Huntington’s disease, where they believe they “own that market.”
In summary, Goorden concluded that IXICO’s strategy involves “expanding further but always in that neurodeenerative disease space which we do believe is very fertile ground.”
Leave a Reply